Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Biotechnology company
|
| gptkbp:acquisition |
Acquired_by_PerkinElmer_in_2020
|
| gptkbp:awards |
Best Company to Work For 2019
Cambridge Business Awards 2018 |
| gptkbp:competitors |
gptkb:Editas_Medicine
gptkb:Thermo_Fisher_Scientific gptkb:Sangamo_Therapeutics gptkb:CRISPR_Therapeutics Illumina |
| gptkbp:customerBase |
Academic institutions
Biopharmaceutical companies |
| gptkbp:employees |
Over 300
|
| gptkbp:focus |
Precision medicine
|
| gptkbp:founded |
2007
|
| gptkbp:founder |
gptkb:Darrin_Disley
|
| gptkbp:headquarters |
gptkb:Cambridge,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Horizon Discovery Limited
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:investmentFocus |
Institutional investors
Private equity firms |
| gptkbp:location |
gptkb:Cambridge
|
| gptkbp:market |
Global biotechnology market
|
| gptkbp:partnerships |
Collaborations with pharmaceutical companies
Partnership with Pfizer Partnership with AstraZeneca Partnership with Merck Partnership_with_GSK Partnership_with_Novartis Partnership_with_Roche |
| gptkbp:products |
Gene_editing_tools
|
| gptkbp:researchFocus |
Cancer research
Genetic disorders Drug discovery Therapeutic development |
| gptkbp:revenue |
£30 million (2020)
|
| gptkbp:services |
Cell line development
Gene modulation |
| gptkbp:specialization |
Genetic research
|
| gptkbp:stockSymbol |
HZD
|
| gptkbp:subsidiary |
gptkb:Horizon_Discovery_(Asia)_Ltd.
gptkb:Horizon_Discovery_(Europe)_Ltd. gptkb:Horizon_Discovery_(US)_Inc. |
| gptkbp:technology |
RNA interference
CRISPR Gene synthesis |
| gptkbp:website |
www.horizondiscovery.com
|